Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE The inhibition of 11β-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production. 31664610 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Therefore, the precise role of 11β-HSD1 in the development of complications associated with the metabolic syndrome has still not been deciphered yet. 30796905 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE 11βHSD1 deficiency enhances myofibroblast activation and promotes initial fibrosis following chemical liver injury; hence, the effects of 11βHSD1 inhibitors on liver injury and repair are likely to be context-dependent and deserve careful scrutiny as these compounds are developed for chronic diseases including metabolic syndrome and dementia.(Hepatology 2018;67:2167-2181). 29251794 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Knockout mice or a selective inhibitor of 11β-HSD1 improves metabolic syndrome parameters in preclinical models and human clinical trials. 30096297 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE It has been reported that too much cortisol or overexpression of HSD11B1 induces obesity and the insulin resistance that accompanies metabolic syndrome in rodent adipose tissue. 29206210 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE The association analysis indicated that HSD11B1 rs12086634 TG contributed to an increased risk of both T2D (OR=1.91; 95% CI-1.33-2.76, P=0.0005) and metS (OR=2.37; 95% CI-1.39-4.05, P=0.0015), but HSD11B1 rs846910 AG contributed to an increased risk of T2D (OR=1.62; 95% CI-1.02-2.57, P=0.03) only. 28750217 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE In addition, the protein expression levels of 11β‑HSD1 and DNA damage inducible transcript 3 were detected and the histopathology of important tissues for metabolic syndrome were analyzed. 28944856 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE In addition, pharmacological approaches aimed at reducing aldosterone and GC levels, by means of the inhibition of CYP11B2 (aldosterone synthase) or 11β-HSD1, represent alternative strategies to counter the detrimental effects of excessive levels of corticosteroids, which are often observed in obesity and, more general, in MetS.© 2017 American Physiological Society.Compr Physiol 7:1425-1447, 2017. 28915330 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE H6PDH and 11β-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes. 28751144 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE The potential role of 11β-HSD1 in the pathogenesis of the metabolic syndrome has emerged over the past three decades. 28765040 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE Due to its implication in glucocorticoid metabolism, the inhibition of 11β-HSD1 activity has become a dominant strategy for the treatment of metabolic syndrome. 26980090 2016
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). 25751397 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Prereceptor activation of glucocorticoid availability in target tissue by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) coupled with hexose-6-phosphate dehydrogenase (H6PDH) is an important mediator of the metabolic syndrome. 25389364 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Taken together with earlier evidence that non-selective inhibitors of 11βHSD1 enhance insulin sensitivity, these results led to the hypothesis that inhibition of 11βHSD1 might be a promising target for treatment of the metabolic syndrome. 24710966 2014
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE These results suggest that 11 β -HSD1 activity in liver and adipose tissue is a common mediator of hypertension, hypertriglyceridemia, glucose intolerance, and insulin resistance in metabolic syndrome. 23586038 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE There was a significant association between the HSD11B1 gene polymorphism (rs12086634) and occurrence of metabolic syndrome compared to controls (P<0.0001). 23869418 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Finally, we will address the current status of selective 11β-HSD1 inhibitors that are in development and being tested in phase II trials for patients with the metabolic syndrome. 23612224 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE In this study, we investigated the association of two 11beta-HSD1 gene (HSD11B1) polymorphisms with the metabolic syndrome (MetS) and its characteristics in the Bosnian population. 22384521 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE GRα and 11β-HSD1 mRNA levels differed among tissues involved in the pathophysiology of metabolic syndrome. 23212335 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE This positive correlation between obesity markers and 11β-HSD-1 in AA and EA tissues strengthens the evidence that 11β-HSD-1 has a role in metabolic syndrome. 23007990 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE Hepatic mRNA levels of these genes were higher in obese patients with MS (11β-HSD1, P = 0.002; H6PDH, P = 0.043; GR, P = 0.033; PEPCK, P = 0.032) and positively correlated with the number of clinical characteristics that define the MS. 21964795 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 AlteredExpression disease BEFREE The expression of omental 11β-HSD1 is not increased in severely obese women with metabolic syndrome. 22433622 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE We conclude that, in a population of Southern European Caucasian women with and without PCOS, alleles of HSD11B1 containing the two SNPs rs846910 A and rs12086634 T confer increased 11β-HSD1 expression and activity, which associates with the metabolic syndrome. 21622477 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 GeneticVariation disease BEFREE In conclusion, HSD11B1 and H6PD polymorphisms may not be associated with type 2 diabetes and metabolic syndrome. 21869537 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.300 Biomarker disease BEFREE The employed hierarchical virtual screening protocol not only demonstrates its efficiency, but also provides novel and selective compounds for developing 11β-HSD1 inhibitors to protect against metabolic syndrome. 21873057 2011